个人中心 - 老虎社区

远离中概股A股股权

IP属地：江苏

帖子 · 502帖子 · 502
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 远离中概股A股股权远离中概股A股股权
  ·12-02
  $诺和诺德(NVO)$ 愿赌服输，跌跌
  373 评论
  1
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-26
  $诺和诺德(NVO)$ 为啥涨？
  947 4
  1
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-21
  $诺和诺德(NVO)$ 这货就是每天都跌
  713 评论
  2
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-20
  我看能成功，神药
  诺和诺德将开展高风险阿尔茨海默病研究
  诺和诺德公司定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。
  诺和诺德将开展高风险阿尔茨海默病研究
  413 评论
  1
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-18
  $诺和诺德(NVO)$ 真是能跌啊，为啥我就买了它[流泪]
  842 2
  3
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-17
  $诺和诺德(NVO)$ 每天都做空它真能赚不少钱
  686 评论
  1
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-14
  $诺和诺德(NVO)$ 有开始漫长的爹爹了
  851 评论
  2
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-13
  $诺和诺德(NVO)$ 咋今天又开始大跌了没有涨几天aiai
  724 评论
  1
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-11
  $诺和诺德(NVO)$ 为啥涨有人知道吗
  2,302 7
  3
  分享
  举报
- 远离中概股A股股权远离中概股A股股权
  ·11-07
  $诺和诺德(NVO)$ 这货不如一次到位跌倒30，何必来个阴跌呢
  974 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3452505216401608","uuid":"3452505216401608","gmtCreate":1492529584078,"gmtModify":1734062313087,"name":"远离中概股A股股权","pinyin":"ylzggaggqyuanlizhonggaiguaguguquan","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"LV3 头像框","vip":1,"status":2,"fanSize":23,"headSize":24,"tweetSize":502,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.11","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.98%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":6,"crmLevelSwitch":1,"location":"江苏","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":12,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":506499408704568,"gmtCreate":1764687764974,"gmtModify":1764687766677,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 愿赌服输，跌跌","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 愿赌服输，跌跌","text":"$诺和诺德(NVO)$ 愿赌服输，跌跌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/506499408704568","isVote":1,"tweetType":1,"viewCount":373,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":504341826573160,"gmtCreate":1764158844982,"gmtModify":1764158847064,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 为啥涨？","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 为啥涨？","text":"$诺和诺德(NVO)$ 为啥涨？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":4,"repostSize":0,"link":"https://laohu8.com/post/504341826573160","isVote":1,"tweetType":1,"viewCount":947,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":502619646448104,"gmtCreate":1763737950486,"gmtModify":1763737952324,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 这货就是每天都跌","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 这货就是每天都跌","text":"$诺和诺德(NVO)$ 这货就是每天都跌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/502619646448104","isVote":1,"tweetType":1,"viewCount":713,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":502279536255080,"gmtCreate":1763645894865,"gmtModify":1763645897360,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"我看能成功，神药","listText":"我看能成功，神药","text":"我看能成功，神药","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/502279536255080","repostId":"2584136350","repostType":2,"repost":{"id":"2584136350","kind":"news","pubTimestamp":1763639700,"share":"https://www.laohu8.com/m/news/2584136350?lang=zh_CN&edition=full","pubTime":"2025-11-20 19:55","market":"other","language":"zh","title":"诺和诺德将开展高风险阿尔茨海默病研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2584136350","media":"环球市场播报","summary":"诺和诺德公司定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。","content":"<html><body><div>\n<p>　　<span><a href=\"https://laohu8.com/S/NVO\">诺和诺德</a></span><span></span>公司（股票代码：NVO、NOVO-B.CO）定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。目前，全球数百万糖尿病患者和减重人群正在使用该类药物。</p>\n<p>　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片（Rybelsus）。该药物与司美格鲁肽注射液（Ozempic，中文商品名 “诺和泰”）、 Wegovy（中文商品名 “诺和盈”）含有相同的活性成分 —— 司美格鲁肽（semaglutide），试验目标是将患者的认知衰退速度降低至少 20%。</p>\n<p>　　阿尔茨海默病领域专家表示，若试验成功，将催生一种便捷的新型疗法，用于延缓这种 “侵蚀大脑” 的疾病进展。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。</p>\n<p>　　无论试验结果如何，研究人员均有望获得重要线索，为未来研究 “GLP-1 类药物（包括<span><a href=\"https://laohu8.com/S/LLY\">礼来</a></span><span></span>公司的 Zepbound 和 Mounjaro）为何及如何对阿尔茨海默病产生潜在疗效” 奠定基础。</p>\n<p>　　“这项研究确实有可能带来变革性影响。” 阿尔茨海默病协会首席科学官玛丽亚・卡里略表示。</p>\n<p>　　她与其他领域专家向路透社透露，目前尚不清楚以 GLP-1 受体为作用靶点的药物如何影响大脑。</p>\n<p>　　目前支持 GLP-1 类药物用于阿尔茨海默病试验的多数证据，均来自其在 “糖尿病合并肥胖相关痴呆患者” 中的应用数据。</p>\n<p>　　诺和诺德一位发言人指出，该公司于 2021 年启动阿尔茨海默病研究，依据包括两方面：一是动物实验证据，二是对人类研究的分析 —— 后者显示，接受 GLP-1 类药物治疗的糖尿病患者，其痴呆或阿尔茨海默病发病风险更低。此外，一项针对该公司早年推出的 GLP-1 类注射剂利拉鲁肽（liraglutide）的小型研究发现，该药物可减缓轻度阿尔茨海默病患者的脑容量流失速度。</p>\n<p>　　<strong>试验成功或推动诺和诺德股价上涨</strong></p>\n<p>　　专家表示，若利拉鲁肽片能延缓早期阿尔茨海默病患者的认知衰退，其安全性和便捷性将优于 “淀粉样蛋白清除类药物”。不过，利拉鲁肽片的用药要求较高：需空腹服用，且服药后 30 分钟内不得进食、饮水或服用其他口服药物。</p>\n<p>　　华尔街分析师预测，若试验明确成功，诺和诺德股价或最高上涨 10%；若试验失败，股价可能下跌 5%。</p>\n<p>　　诺和诺德计划于 12 月 3 日在圣地亚哥举行的 “阿尔茨海默病临床试验会议” 上公布试验结果，但也可能在此之前提前披露部分数据。</p>\n<p>　　“从市场推广角度看，一款安全的口服药物意义重大。这类药物的（上市）门槛会非常低。” 诺普曼（Knopman）表示。</p>\n<p>　　<strong>GLP-1 类药物对大脑的作用机制尚不明确</strong></p>\n<p>　　约 60% 的痴呆患者为阿尔茨海默病患者，其余患者则患有血管性痴呆（由脑部血流受阻引发）等疾病，且许多患者同时患有多种类型的痴呆。</p>\n<p>　　纽约西奈山医院阿尔茨海默病研究员、该试验项目研究者玛丽・萨诺博士指出，由于试验要求所有参与者需确诊为阿尔茨海默病，因此难以招募同时患有血管性痴呆的患者 —— 这类患者在糖尿病群体中较为常见，但他们的病情通常已进展到不符合试验入组标准的阶段。</p>\n<p>　　<strong>目前在理解 GLP-1 类药物对大脑作用方面存在哪些挑战？</strong></p>\n<p>　　科学家表示，此前研究中 GLP-1 类药物降低痴呆风险的具体机制仍不明确。可能的作用路径包括两种：一是药物直接对大脑产生影响；二是药物通过减重、减轻体内炎症等间接改善身体状态，进而保护大脑。</p>\n<p>　　此外，并非所有 GLP-1 类药物的作用都相同。弗吉尼亚大学内分泌学家希瑟・费里斯博士指出，小鼠实验显示，利拉鲁肽（商品名：Victoza “诺和力”、Saxenda “诺和盈”）进入大脑的难度低于司美格鲁肽。</p>\n<p>　　费里斯预计，诺和诺德的此次研究 “可能会取得阳性结果，但效果有限”。</p>\n<p>　　明尼苏达州罗切斯特市梅奥诊所神经科医生戴维・诺普曼博士表示：“目前完全不清楚大脑中的 GLP-1 靶点与阿尔茨海默病病理之间存在何种关联，这并非一个积极信号。”</p>\n<p>　　目前全球已批准两款通过清除大脑淀粉样蛋白来延缓阿尔茨海默病的药物：礼来公司的 Kisunla，以及卫材（Eisai）与渤健（Biogen）联合研发的 Leqembi（中文商品名 “仑卡奈单抗”）。这两款药物均通过输液或注射给药，临床试验显示其可将疾病进展速度减缓近 30%，但同时存在严重副作用风险，且需定期进行影像学检查。</p>\n<p>　　<strong>试验结果或为未来研究指明方向</strong></p>\n<p>　　阿尔茨海默病药物研发基金会（该机构为包括利拉鲁肽研究在内的多个阿尔茨海默病研究项目提供资金支持）的霍华德・菲利特博士表示，诺和诺德的试验或可揭示 GLP-1 类药物对 “大脑代谢年龄相关变化” 的影响 —— 这类变化发生在淀粉样蛋白斑块形成之前。</p>\n<p>　　他指出，若利拉鲁肽片能将认知衰退速度减缓近 30%，该研究将被视为明确成功。</p>\n<p>　　菲利特补充称，即便未达到这一目标，试验结果也能为未来的试验设计提供指导，包括探索 GLP-1 类药物与现有阿尔茨海默病药物联合使用的可能性。</p>\n<p>　　礼来公司表示，将 “持续密切关注不断发展的科学研究，以更好地理解 GLP-1 类药物在大脑健康中的作用”。目前，礼来正开展一项研究，探索 Kisunla 能否在阿尔茨海默病症状出现前预防疾病发生，该试验预计于 2027 年结束。</p>\n<p>　　卫材与渤健也在针对 Leqembi 开展类似的预防研究。卫材在一份声明中表示，若诺和诺德的试验能证明司美格鲁肽具有显著临床益处，该药物或可成为 Leqembi 等药物的补充治疗选择。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：郭明煜 </p>\n</div></body></html>","source":"sina","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>诺和诺德将开展高风险阿尔茨海默病研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n诺和诺德将开展高风险阿尔茨海默病研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-20 19:55 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2025-11-20/doc-infyafyr2509688.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>诺和诺德公司（股票代码：NVO、NOVO-B.CO）定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。目前，全球数百万糖尿病患者和减重人群正在使用该类药物。\n　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片（Rybelsus）。该药物与司美格鲁肽注射液（...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-11-20/doc-infyafyr2509688.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVO":"诺和诺德","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓"},"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-11-20/doc-infyafyr2509688.shtml","is_english":false,"share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","article_id":"2584136350","content_text":"诺和诺德公司（股票代码：NVO、NOVO-B.CO）定于下月初公布的研究数据，将首次为 “重磅 GLP-1 类药物能否延缓阿尔茨海默病进展” 提供最有力的线索。目前，全球数百万糖尿病患者和减重人群正在使用该类药物。\n　　诺和诺德将两项试验称为 “幸运彩票”，试验对象为数千名轻度阿尔茨海默病患者，测试药物是其早年推出的糖尿病口服药利拉鲁肽片（Rybelsus）。该药物与司美格鲁肽注射液（Ozempic，中文商品名 “诺和泰”）、 Wegovy（中文商品名 “诺和盈”）含有相同的活性成分 —— 司美格鲁肽（semaglutide），试验目标是将患者的认知衰退速度降低至少 20%。\n　　阿尔茨海默病领域专家表示，若试验成功，将催生一种便捷的新型疗法，用于延缓这种 “侵蚀大脑” 的疾病进展。阿尔茨海默病的特征是大脑中出现毒性淀粉样蛋白斑块，目前全球患者已达 5000 万人。\n　　无论试验结果如何，研究人员均有望获得重要线索，为未来研究 “GLP-1 类药物（包括礼来公司的 Zepbound 和 Mounjaro）为何及如何对阿尔茨海默病产生潜在疗效” 奠定基础。\n　　“这项研究确实有可能带来变革性影响。” 阿尔茨海默病协会首席科学官玛丽亚・卡里略表示。\n　　她与其他领域专家向路透社透露，目前尚不清楚以 GLP-1 受体为作用靶点的药物如何影响大脑。\n　　目前支持 GLP-1 类药物用于阿尔茨海默病试验的多数证据，均来自其在 “糖尿病合并肥胖相关痴呆患者” 中的应用数据。\n　　诺和诺德一位发言人指出，该公司于 2021 年启动阿尔茨海默病研究，依据包括两方面：一是动物实验证据，二是对人类研究的分析 —— 后者显示，接受 GLP-1 类药物治疗的糖尿病患者，其痴呆或阿尔茨海默病发病风险更低。此外，一项针对该公司早年推出的 GLP-1 类注射剂利拉鲁肽（liraglutide）的小型研究发现，该药物可减缓轻度阿尔茨海默病患者的脑容量流失速度。\n　　试验成功或推动诺和诺德股价上涨\n　　专家表示，若利拉鲁肽片能延缓早期阿尔茨海默病患者的认知衰退，其安全性和便捷性将优于 “淀粉样蛋白清除类药物”。不过，利拉鲁肽片的用药要求较高：需空腹服用，且服药后 30 分钟内不得进食、饮水或服用其他口服药物。\n　　华尔街分析师预测，若试验明确成功，诺和诺德股价或最高上涨 10%；若试验失败，股价可能下跌 5%。\n　　诺和诺德计划于 12 月 3 日在圣地亚哥举行的 “阿尔茨海默病临床试验会议” 上公布试验结果，但也可能在此之前提前披露部分数据。\n　　“从市场推广角度看，一款安全的口服药物意义重大。这类药物的（上市）门槛会非常低。” 诺普曼（Knopman）表示。\n　　GLP-1 类药物对大脑的作用机制尚不明确\n　　约 60% 的痴呆患者为阿尔茨海默病患者，其余患者则患有血管性痴呆（由脑部血流受阻引发）等疾病，且许多患者同时患有多种类型的痴呆。\n　　纽约西奈山医院阿尔茨海默病研究员、该试验项目研究者玛丽・萨诺博士指出，由于试验要求所有参与者需确诊为阿尔茨海默病，因此难以招募同时患有血管性痴呆的患者 —— 这类患者在糖尿病群体中较为常见，但他们的病情通常已进展到不符合试验入组标准的阶段。\n　　目前在理解 GLP-1 类药物对大脑作用方面存在哪些挑战？\n　　科学家表示，此前研究中 GLP-1 类药物降低痴呆风险的具体机制仍不明确。可能的作用路径包括两种：一是药物直接对大脑产生影响；二是药物通过减重、减轻体内炎症等间接改善身体状态，进而保护大脑。\n　　此外，并非所有 GLP-1 类药物的作用都相同。弗吉尼亚大学内分泌学家希瑟・费里斯博士指出，小鼠实验显示，利拉鲁肽（商品名：Victoza “诺和力”、Saxenda “诺和盈”）进入大脑的难度低于司美格鲁肽。\n　　费里斯预计，诺和诺德的此次研究 “可能会取得阳性结果，但效果有限”。\n　　明尼苏达州罗切斯特市梅奥诊所神经科医生戴维・诺普曼博士表示：“目前完全不清楚大脑中的 GLP-1 靶点与阿尔茨海默病病理之间存在何种关联，这并非一个积极信号。”\n　　目前全球已批准两款通过清除大脑淀粉样蛋白来延缓阿尔茨海默病的药物：礼来公司的 Kisunla，以及卫材（Eisai）与渤健（Biogen）联合研发的 Leqembi（中文商品名 “仑卡奈单抗”）。这两款药物均通过输液或注射给药，临床试验显示其可将疾病进展速度减缓近 30%，但同时存在严重副作用风险，且需定期进行影像学检查。\n　　试验结果或为未来研究指明方向\n　　阿尔茨海默病药物研发基金会（该机构为包括利拉鲁肽研究在内的多个阿尔茨海默病研究项目提供资金支持）的霍华德・菲利特博士表示，诺和诺德的试验或可揭示 GLP-1 类药物对 “大脑代谢年龄相关变化” 的影响 —— 这类变化发生在淀粉样蛋白斑块形成之前。\n　　他指出，若利拉鲁肽片能将认知衰退速度减缓近 30%，该研究将被视为明确成功。\n　　菲利特补充称，即便未达到这一目标，试验结果也能为未来的试验设计提供指导，包括探索 GLP-1 类药物与现有阿尔茨海默病药物联合使用的可能性。\n　　礼来公司表示，将 “持续密切关注不断发展的科学研究，以更好地理解 GLP-1 类药物在大脑健康中的作用”。目前，礼来正开展一项研究，探索 Kisunla 能否在阿尔茨海默病症状出现前预防疾病发生，该试验预计于 2027 年结束。\n　　卫材与渤健也在针对 Leqembi 开展类似的预防研究。卫材在一份声明中表示，若诺和诺德的试验能证明司美格鲁肽具有显著临床益处，该药物或可成为 Leqembi 等药物的补充治疗选择。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","news_type":1,"symbols_score_info":{"NVO":1.5}},"isVote":1,"tweetType":1,"viewCount":413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":501564220715552,"gmtCreate":1763459700158,"gmtModify":1763459702096,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 真是能跌啊，为啥我就买了它[流泪]&nbsp;&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 真是能跌啊，为啥我就买了它[流泪]&nbsp;&nbsp;","text":"$诺和诺德(NVO)$ 真是能跌啊，为啥我就买了它[流泪]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/501564220715552","isVote":1,"tweetType":1,"viewCount":842,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4110747462729630","authorId":"4110747462729630","name":"亏完就走","avatar":"https://static.tigerbbs.com/4239473bbf98759e23c8d47fcde2c29e","crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"4110747462729630","idStr":"4110747462729630"},"content":"等个历史最低位上车😊😊","text":"等个历史最低位上车😊😊","html":"等个历史最低位上车😊😊"},{"author":{"id":"3546249304196282","authorId":"3546249304196282","name":"火火兔爸","avatar":"https://static.tigerbbs.com/1914631c23e50a7645217a36cc9d9598","crmLevel":9,"crmLevelSwitch":1,"authorIdStr":"3546249304196282","idStr":"3546249304196282"},"content":"因为你嫌礼来贵，贪便宜。","text":"因为你嫌礼来贵，贪便宜。","html":"因为你嫌礼来贵，贪便宜。"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":501171437219968,"gmtCreate":1763386284451,"gmtModify":1763386286191,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 每天都做空它真能赚不少钱","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 每天都做空它真能赚不少钱","text":"$诺和诺德(NVO)$ 每天都做空它真能赚不少钱","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/501171437219968","isVote":1,"tweetType":1,"viewCount":686,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":499931420983376,"gmtCreate":1763079074672,"gmtModify":1763079076347,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 有开始漫长的爹爹了","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 有开始漫长的爹爹了","text":"$诺和诺德(NVO)$ 有开始漫长的爹爹了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/499931420983376","isVote":1,"tweetType":1,"viewCount":851,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":499760089129848,"gmtCreate":1763036816157,"gmtModify":1763038933024,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 咋今天又开始大跌了 没有涨几天aiai","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 咋今天又开始大跌了 没有涨几天aiai","text":"$诺和诺德(NVO)$ 咋今天又开始大跌了 没有涨几天aiai","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/499760089129848","isVote":1,"tweetType":1,"viewCount":724,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":499085438677720,"gmtCreate":1762871987896,"gmtModify":1762871989804,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 为啥涨 有人知道吗","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 为啥涨 有人知道吗","text":"$诺和诺德(NVO)$ 为啥涨 有人知道吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":7,"repostSize":0,"link":"https://laohu8.com/post/499085438677720","isVote":1,"tweetType":1,"viewCount":2302,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3561532925843785","authorId":"3561532925843785","name":"股市小六","avatar":"https://static.tigerbbs.com/93351464cd1b89c41fc5f874c63be0d1","crmLevel":5,"crmLevelSwitch":1,"authorIdStr":"3561532925843785","idStr":"3561532925843785"},"content":"天天跌，突然一涨还慌了 😂","text":"天天跌，突然一涨还慌了 😂","html":"天天跌，突然一涨还慌了 😂"},{"author":{"id":"3574718097407891","authorId":"3574718097407891","name":"别买期权","avatar":"https://static.tigerbbs.com/f99b61dad72dd027a528242e56f725ae","crmLevel":6,"crmLevelSwitch":1,"authorIdStr":"3574718097407891","idStr":"3574718097407891"},"content":"你猜川普打压他是为了啥","text":"你猜川普打压他是为了啥","html":"你猜川普打压他是为了啥"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":497580454391896,"gmtCreate":1762502425848,"gmtModify":1762502427689,"author":{"id":"3452505216401608","authorId":"3452505216401608","name":"远离中概股A股股权","avatar":"https://static.tigerbbs.com/a18f4cd278fe8bb0f92da299201fb953","crmLevel":6,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3452505216401608","idStr":"3452505216401608"},"themes":[],"title":"","htmlText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 这货不如一次到位跌倒30，何必来个阴跌呢","listText":"<a href=\"https://laohu8.com/S/NVO\">$诺和诺德(NVO)$&nbsp;</a> 这货不如一次到位跌倒30，何必来个阴跌呢","text":"$诺和诺德(NVO)$ 这货不如一次到位跌倒30，何必来个阴跌呢","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/497580454391896","isVote":1,"tweetType":1,"viewCount":974,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}